BUCET
Clinical safety rating: caution
Comprehensive clinical and safety monograph for BUCET (BUCET).
Bucet is a combination of bucetin and acetaminophen. Bucetin is a para-aminophenol derivative with analgesic and antipyretic effects, possibly through inhibition of cyclooxygenase in the central nervous system. Acetaminophen inhibits COX enzymes in the brain, reducing prostaglandin synthesis and fever.
| Metabolism | Bucetin: Hepatic metabolism via hydroxylation and glucuronidation. Acetaminophen: Hepatic metabolism via glucuronidation, sulfation, and CYP2E1-mediated oxidation to NAPQI. |
| Excretion | Renal: ~70% unchanged; biliary/fecal: ~30% as metabolites |
| Half-life | 2-4 hours (terminal); prolonged in renal impairment |
| Protein binding | ~85% bound to albumin |
| Volume of Distribution | 0.3-0.5 L/kg; distributes primarily into extracellular fluid |
| Bioavailability | Oral: 75-90% |
| Onset of Action | Oral: 30-60 minutes; IV: 5-10 minutes |
| Duration of Action | 4-6 hours; may be extended with sustained-release formulations |
| Molecular Weight | 310.4 |
Oral: 25-50 mg every 4-6 hours as needed for pain; maximum 200 mg/day.
| Dosage form | CAPSULE |
| Renal impairment | GFR 10-50 mL/min: 50% dose reduction; GFR <10 mL/min: avoid use. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: 50% dose reduction; Child-Pugh C: avoid use. |
| Pediatric use | Children 6-12 years: 5 mg/kg/dose every 6 hours as needed; maximum 20 mg/kg/day. |
| Geriatric use | Start at lowest effective dose (12.5 mg every 6 hours); maximum 150 mg/day due to increased fall risk and renal impairment. |
| 1st trimester | Potential risk of fetal harm based on animal data; use only if benefit outweighs risk. |
| 2nd trimester | No well-controlled human studies; consider alternative agents with more safety data. |
| 3rd trimester | Risk of adverse fetal effects, including possible premature closure of ductus arteriosus and oligohydramnios; avoid in third trimester. |
Clinical note
Comprehensive clinical and safety monograph for BUCET (BUCET).
| Placental transfer | Crosses the placenta in animal studies; human data limited but assumed transfer given molecular weight. |
| Breastfeeding | Limited human data; low levels may be excreted into breast milk. Use with caution, monitor infant for adverse effects. |
| Lactation Rating |
■ FDA Black Box Warning
No FDA black box warnings for bucet. Acetaminophen component: Risk of severe liver injury at high doses or with alcohol use.
| Serious Effects |
Severe hepatic impairmentHypersensitivity to bucetin or any componentActive peptic ulcer diseaseHistory of asthma induced by NSAIDs
| Precautions | Hepatotoxicity risk with acetaminophen overdose, Avoid alcohol use, Hypersensitivity reactions, Skin reactions (Stevens-Johnson syndrome) |
| Food/Dietary | No known food interactions. Avoid alcohol as it may increase risk of side effects like dizziness. |
| Clinical Pearls |
Loading safety data…
| L3 (Moderately Safe) |
| Teratogenic Risk | FDA Pregnancy Category D. First trimester: Increased risk of cardiac malformations and neural tube defects. Second and third trimesters: Risk of premature closure of ductus arteriosus, oligohydramnios, and neonatal renal impairment. |
| Fetal Monitoring | Monitor maternal renal function, hepatic function, and blood pressure. Fetal ultrasound for ductus arteriosus and amniotic fluid index. Neonatal monitoring for renal function and respiratory status. |
| Fertility Effects | May cause reversible infertility due to ovulatory dysfunction. Animal studies show reduced fertility at high doses. |
| Bucet (bupivacaine hydrochloride and epinephrine) is used for local anesthesia. Epinephrine prolongs anesthetic effect and reduces systemic absorption. Avoid in patients with severe hypertension, hyperthyroidism, or concurrent MAO inhibitors. Monitor for CNS and cardiac toxicity, especially with high doses. Epinephrine concentration is 1:200,000; check for allergy to sulfites (antioxidant). |
| Patient Advice | Do not drive or operate machinery until numbness subsides. · Avoid touching or scratching the numb area to prevent injury. · Report any signs of allergic reaction (rash, swelling, difficulty breathing) or intravenous injection symptoms (rapid heart rate, anxiety, headache). · The numbness will wear off over several hours depending on the dose and site. |